Selected research
Market Outlook & Growth Opportunities
Global Sialylated Human Milk Oligosaccharides (HMO) Market Outlook and Growth Opportunities 2026
Market perspective
The global Sialylated Human Milk Oligosaccharides (HMO) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Sialylated Human Milk Oligosaccharides (HMO) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Sialylated Human Milk Oligosaccharides (HMO) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Sialylated Human Milk Oligosaccharides (HMO) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Sialylated Human Milk Oligosaccharides (HMO) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Sialylated Human Milk Oligosaccharides (HMO) market include Chr. Hansen (Jennewein Biotechnologie GmgH), DSM (Glycom A/S), Inbiose, Kyowa Hakko Bio, GeneChem Inc. and FrieslandCampina Ingredients, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Sialylated Human Milk Oligosaccharides (HMO) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Sialylated Human Milk Oligosaccharides (HMO) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Sialylated Human Milk Oligosaccharides (HMO) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Sialylated Human Milk Oligosaccharides (HMO) market size, projected growth trends, production technologies, key applications, and end-use industries.
Sialylated Human Milk Oligosaccharides (HMO) Segment by Company
Chr. Hansen (Jennewein Biotechnologie GmgH)
DSM (Glycom A/S)
Inbiose
Kyowa Hakko Bio
GeneChem Inc.
FrieslandCampina Ingredients
Sialylated Human Milk Oligosaccharides (HMO) Segment by Type
3'-Sialyllactose
6'-Sialyllactose
Sialylated Human Milk Oligosaccharides (HMO) Segment by Application
Infant Formula
Food
Others
Sialylated Human Milk Oligosaccharides (HMO) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Sialylated Human Milk Oligosaccharides (HMO) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Sialylated Human Milk Oligosaccharides (HMO) market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Sialylated Human Milk Oligosaccharides (HMO) significant trends, drivers, influence factors in global and regions.
6. To analyze Sialylated Human Milk Oligosaccharides (HMO) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sialylated Human Milk Oligosaccharides (HMO) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Sialylated Human Milk Oligosaccharides (HMO) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sialylated Human Milk Oligosaccharides (HMO).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Sialylated Human Milk Oligosaccharides (HMO) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Sialylated Human Milk Oligosaccharides (HMO) industry.
Chapter 3: Detailed analysis of Sialylated Human Milk Oligosaccharides (HMO) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Sialylated Human Milk Oligosaccharides (HMO) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Sialylated Human Milk Oligosaccharides (HMO) in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- 3'-Sialyllactose
- 6'-Sialyllactose
Applications
- Infant Formula
- Food
- Others
Companies covered
- Chr. Hansen (Jennewein Biotechnologie GmgH)
- DSM (Glycom A/S)
- Inbiose
- Kyowa Hakko Bio
- GeneChem Inc.
- FrieslandCampina Ingredients
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Sialylated Human Milk Oligosaccharides (HMO) Sales Value (2021-2032)
- 1.2.2 Global Sialylated Human Milk Oligosaccharides (HMO) Sales Volume (2021-2032)
- 1.2.3 Global Sialylated Human Milk Oligosaccharides (HMO) Sales Average Price (2021-2032)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
2 Sialylated Human Milk Oligosaccharides (HMO) Market Dynamics
- 2.1 Sialylated Human Milk Oligosaccharides (HMO) Industry Trends
- 2.2 Sialylated Human Milk Oligosaccharides (HMO) Industry Drivers
- 2.3 Sialylated Human Milk Oligosaccharides (HMO) Industry Opportunities and Challenges
- 2.4 Sialylated Human Milk Oligosaccharides (HMO) Industry Restraints
3 Sialylated Human Milk Oligosaccharides (HMO) Market by Company
- 3.1 Global Sialylated Human Milk Oligosaccharides (HMO) Company Revenue Ranking in 2025
- 3.2 Global Sialylated Human Milk Oligosaccharides (HMO) Revenue by Company (2021-2026)
- 3.3 Global Sialylated Human Milk Oligosaccharides (HMO) Sales Volume by Company (2021-2026)
- 3.4 Global Sialylated Human Milk Oligosaccharides (HMO) Average Price by Company (2021-2026)
- 3.5 Global Sialylated Human Milk Oligosaccharides (HMO) Company Ranking (2024-2026)
- 3.6 Global Sialylated Human Milk Oligosaccharides (HMO) Company Manufacturing Base and Headquarters
- 3.7 Global Sialylated Human Milk Oligosaccharides (HMO) Company Product Type and Application
- 3.8 Global Sialylated Human Milk Oligosaccharides (HMO) Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Sialylated Human Milk Oligosaccharides (HMO) Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.9.3 2025 Sialylated Human Milk Oligosaccharides (HMO) Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
4 Sialylated Human Milk Oligosaccharides (HMO) Market by Type
- 4.1 Sialylated Human Milk Oligosaccharides (HMO) Type Introduction
- 4.1.1 3'-Sialyllactose
- 4.1.2 6'-Sialyllactose
- 4.2 Global Sialylated Human Milk Oligosaccharides (HMO) Sales Volume by Type
- 4.2.1 Global Sialylated Human Milk Oligosaccharides (HMO) Sales Volume by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Sialylated Human Milk Oligosaccharides (HMO) Sales Volume by Type (2021-2032)
- 4.2.3 Global Sialylated Human Milk Oligosaccharides (HMO) Sales Volume Share by Type (2021-2032)
- 4.3 Global Sialylated Human Milk Oligosaccharides (HMO) Sales Value by Type
- 4.3.1 Global Sialylated Human Milk Oligosaccharides (HMO) Sales Value by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Sialylated Human Milk Oligosaccharides (HMO) Sales Value by Type (2021-2032)
- 4.3.3 Global Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Type (2021-2032)
5 Sialylated Human Milk Oligosaccharides (HMO) Market by Application
- 5.1 Sialylated Human Milk Oligosaccharides (HMO) Application Introduction
- 5.1.1 Infant Formula
- 5.1.2 Food
- 5.1.3 Others
- 5.2 Global Sialylated Human Milk Oligosaccharides (HMO) Sales Volume by Application
- 5.2.1 Global Sialylated Human Milk Oligosaccharides (HMO) Sales Volume by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Sialylated Human Milk Oligosaccharides (HMO) Sales Volume by Application (2021-2032)
- 5.2.3 Global Sialylated Human Milk Oligosaccharides (HMO) Sales Volume Share by Application (2021-2032)
- 5.3 Global Sialylated Human Milk Oligosaccharides (HMO) Sales Value by Application
- 5.3.1 Global Sialylated Human Milk Oligosaccharides (HMO) Sales Value by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Sialylated Human Milk Oligosaccharides (HMO) Sales Value by Application (2021-2032)
- 5.3.3 Global Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Application (2021-2032)
6 Sialylated Human Milk Oligosaccharides (HMO) Regional Sales and Value Analysis
- 6.1 Global Sialylated Human Milk Oligosaccharides (HMO) Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Sialylated Human Milk Oligosaccharides (HMO) Sales by Region (2021-2032)
- 6.2.1 Global Sialylated Human Milk Oligosaccharides (HMO) Sales by Region: 2021-2026
- 6.2.2 Global Sialylated Human Milk Oligosaccharides (HMO) Sales by Region (2027-2032)
- 6.3 Global Sialylated Human Milk Oligosaccharides (HMO) Sales Value by Region: 2021 VS 2025 VS 2032
- 6.4 Global Sialylated Human Milk Oligosaccharides (HMO) Sales Value by Region (2021-2032)
- 6.4.1 Global Sialylated Human Milk Oligosaccharides (HMO) Sales Value by Region: 2021-2026
- 6.4.2 Global Sialylated Human Milk Oligosaccharides (HMO) Sales Value by Region (2027-2032)
- 6.5 Global Sialylated Human Milk Oligosaccharides (HMO) Market Price Analysis by Region (2021-2026)
- 6.6 North America
- 6.6.1 North America Sialylated Human Milk Oligosaccharides (HMO) Sales Value (2021-2032)
- 6.6.2 North America Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Country, 2025 VS 2032
- 6.7 Europe
- 6.7.1 Europe Sialylated Human Milk Oligosaccharides (HMO) Sales Value (2021-2032)
- 6.7.2 Europe Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Country, 2025 VS 2032
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Sialylated Human Milk Oligosaccharides (HMO) Sales Value (2021-2032)
- 6.8.2 Asia-Pacific Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Country, 2025 VS 2032
- 6.9 South America
- 6.9.1 South America Sialylated Human Milk Oligosaccharides (HMO) Sales Value (2021-2032)
- 6.9.2 South America Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Country, 2025 VS 2032
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Sialylated Human Milk Oligosaccharides (HMO) Sales Value (2021-2032)
- 6.10.2 Middle East & Africa Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Country, 2025 VS 2032
7 Sialylated Human Milk Oligosaccharides (HMO) Country-level Sales and Value Analysis
- 7.1 Global Sialylated Human Milk Oligosaccharides (HMO) Sales by Country: 2021 VS 2025 VS 2032
- 7.2 Global Sialylated Human Milk Oligosaccharides (HMO) Sales Value by Country: 2021 VS 2025 VS 2032
- 7.3 Global Sialylated Human Milk Oligosaccharides (HMO) Sales by Country (2021-2032)
- 7.3.1 Global Sialylated Human Milk Oligosaccharides (HMO) Sales by Country (2021-2026)
- 7.3.2 Global Sialylated Human Milk Oligosaccharides (HMO) Sales by Country (2027-2032)
- 7.4 Global Sialylated Human Milk Oligosaccharides (HMO) Sales Value by Country (2021-2032)
- 7.4.1 Global Sialylated Human Milk Oligosaccharides (HMO) Sales Value by Country (2021-2026)
- 7.4.2 Global Sialylated Human Milk Oligosaccharides (HMO) Sales Value by Country (2027-2032)
- 7.5 USA
- 7.5.1 USA Sialylated Human Milk Oligosaccharides (HMO) Sales Value Growth Rate (2021-2032)
- 7.5.2 USA Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Type, 2025 VS 2032
- 7.5.3 USA Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Application, 2025 VS 2032
- 7.6 Canada
- 7.6.1 Canada Sialylated Human Milk Oligosaccharides (HMO) Sales Value Growth Rate (2021-2032)
- 7.6.2 Canada Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Canada Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Application, 2025 VS 2032
- 7.7 Mexico
- 7.6.1 Mexico Sialylated Human Milk Oligosaccharides (HMO) Sales Value Growth Rate (2021-2032)
- 7.6.2 Mexico Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Mexico Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Application, 2025 VS 2032
- 7.8 Germany
- 7.8.1 Germany Sialylated Human Milk Oligosaccharides (HMO) Sales Value Growth Rate (2021-2032)
- 7.8.2 Germany Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Type, 2025 VS 2032
- 7.8.3 Germany Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Application, 2025 VS 2032
- 7.9 France
- 7.9.1 France Sialylated Human Milk Oligosaccharides (HMO) Sales Value Growth Rate (2021-2032)
- 7.9.2 France Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Type, 2025 VS 2032
- 7.9.3 France Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Application, 2025 VS 2032
- 7.10 U.K.
- 7.10.1 U.K. Sialylated Human Milk Oligosaccharides (HMO) Sales Value Growth Rate (2021-2032)
- 7.10.2 U.K. Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Type, 2025 VS 2032
- 7.10.3 U.K. Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Application, 2025 VS 2032
- 7.11 Italy
- 7.11.1 Italy Sialylated Human Milk Oligosaccharides (HMO) Sales Value Growth Rate (2021-2032)
- 7.11.2 Italy Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Italy Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Application, 2025 VS 2032
- 7.12 Spain
- 7.12.1 Spain Sialylated Human Milk Oligosaccharides (HMO) Sales Value Growth Rate (2021-2032)
- 7.12.2 Spain Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Spain Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Application, 2025 VS 2032
- 7.13 Russia
- 7.13.1 Russia Sialylated Human Milk Oligosaccharides (HMO) Sales Value Growth Rate (2021-2032)
- 7.13.2 Russia Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Russia Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Application, 2025 VS 2032
- 7.14 Netherlands
- 7.14.1 Netherlands Sialylated Human Milk Oligosaccharides (HMO) Sales Value Growth Rate (2021-2032)
- 7.14.2 Netherlands Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Type, 2025 VS 2032
- 7.14.3 Netherlands Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Application, 2025 VS 2032
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Sialylated Human Milk Oligosaccharides (HMO) Sales Value Growth Rate (2021-2032)
- 7.15.2 Nordic Countries Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Nordic Countries Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Application, 2025 VS 2032
- 7.16 China
- 7.16.1 China Sialylated Human Milk Oligosaccharides (HMO) Sales Value Growth Rate (2021-2032)
- 7.16.2 China Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Type, 2025 VS 2032
- 7.16.3 China Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Application, 2025 VS 2032
- 7.17 Japan
- 7.17.1 Japan Sialylated Human Milk Oligosaccharides (HMO) Sales Value Growth Rate (2021-2032)
- 7.17.2 Japan Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Type, 2025 VS 2032
- 7.17.3 Japan Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Application, 2025 VS 2032
- 7.18 South Korea
- 7.18.1 South Korea Sialylated Human Milk Oligosaccharides (HMO) Sales Value Growth Rate (2021-2032)
- 7.18.2 South Korea Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Type, 2025 VS 2032
- 7.18.3 South Korea Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Application, 2025 VS 2032
- 7.19 India
- 7.19.1 India Sialylated Human Milk Oligosaccharides (HMO) Sales Value Growth Rate (2021-2032)
- 7.19.2 India Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Type, 2025 VS 2032
- 7.19.3 India Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Application, 2025 VS 2032
- 7.20 Australia
- 7.20.1 Australia Sialylated Human Milk Oligosaccharides (HMO) Sales Value Growth Rate (2021-2032)
- 7.20.2 Australia Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Australia Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Application, 2025 VS 2032
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Sialylated Human Milk Oligosaccharides (HMO) Sales Value Growth Rate (2021-2032)
- 7.21.2 Southeast Asia Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Southeast Asia Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Application, 2025 VS 2032
- 7.22 Brazil
- 7.22.1 Brazil Sialylated Human Milk Oligosaccharides (HMO) Sales Value Growth Rate (2021-2032)
- 7.22.2 Brazil Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Brazil Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Application, 2025 VS 2032
- 7.23 Argentina
- 7.23.1 Argentina Sialylated Human Milk Oligosaccharides (HMO) Sales Value Growth Rate (2021-2032)
- 7.23.2 Argentina Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Argentina Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Application, 2025 VS 2032
- 7.24 Chile
- 7.24.1 Chile Sialylated Human Milk Oligosaccharides (HMO) Sales Value Growth Rate (2021-2032)
- 7.24.2 Chile Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Chile Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Application, 2025 VS 2032
- 7.25 Colombia
- 7.25.1 Colombia Sialylated Human Milk Oligosaccharides (HMO) Sales Value Growth Rate (2021-2032)
- 7.25.2 Colombia Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Colombia Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Application, 2025 VS 2032
- 7.26 Peru
- 7.26.1 Peru Sialylated Human Milk Oligosaccharides (HMO) Sales Value Growth Rate (2021-2032)
- 7.26.2 Peru Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Peru Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Application, 2025 VS 2032
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Sialylated Human Milk Oligosaccharides (HMO) Sales Value Growth Rate (2021-2032)
- 7.27.2 Saudi Arabia Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Type, 2025 VS 2032
- 7.27.3 Saudi Arabia Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Application, 2025 VS 2032
- 7.28 Israel
- 7.28.1 Israel Sialylated Human Milk Oligosaccharides (HMO) Sales Value Growth Rate (2021-2032)
- 7.28.2 Israel Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Israel Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Application, 2025 VS 2032
- 7.29 UAE
- 7.29.1 UAE Sialylated Human Milk Oligosaccharides (HMO) Sales Value Growth Rate (2021-2032)
- 7.29.2 UAE Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Type, 2025 VS 2032
- 7.29.3 UAE Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Application, 2025 VS 2032
- 7.30 Turkey
- 7.30.1 Turkey Sialylated Human Milk Oligosaccharides (HMO) Sales Value Growth Rate (2021-2032)
- 7.30.2 Turkey Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Turkey Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Application, 2025 VS 2032
- 7.31 Iran
- 7.31.1 Iran Sialylated Human Milk Oligosaccharides (HMO) Sales Value Growth Rate (2021-2032)
- 7.31.2 Iran Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Type, 2025 VS 2032
- 7.31.3 Iran Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Application, 2025 VS 2032
- 7.32 Egypt
- 7.32.1 Egypt Sialylated Human Milk Oligosaccharides (HMO) Sales Value Growth Rate (2021-2032)
- 7.32.2 Egypt Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Type, 2025 VS 2032
- 7.32.3 Egypt Sialylated Human Milk Oligosaccharides (HMO) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Chr. Hansen (Jennewein Biotechnologie GmgH)
- 8.1.1 Chr. Hansen (Jennewein Biotechnologie GmgH) Company Information
- 8.1.2 Chr. Hansen (Jennewein Biotechnologie GmgH) Business Overview
- 8.1.3 Chr. Hansen (Jennewein Biotechnologie GmgH) Sialylated Human Milk Oligosaccharides (HMO) Sales, Value and Gross Margin (2021-2026)
- 8.1.4 Chr. Hansen (Jennewein Biotechnologie GmgH) Sialylated Human Milk Oligosaccharides (HMO) Product Portfolio
- 8.1.5 Chr. Hansen (Jennewein Biotechnologie GmgH) Recent Developments
- 8.2 DSM (Glycom A/S)
- 8.2.1 DSM (Glycom A/S) Company Information
- 8.2.2 DSM (Glycom A/S) Business Overview
- 8.2.3 DSM (Glycom A/S) Sialylated Human Milk Oligosaccharides (HMO) Sales, Value and Gross Margin (2021-2026)
- 8.2.4 DSM (Glycom A/S) Sialylated Human Milk Oligosaccharides (HMO) Product Portfolio
- 8.2.5 DSM (Glycom A/S) Recent Developments
- 8.3 Inbiose
- 8.3.1 Inbiose Company Information
- 8.3.2 Inbiose Business Overview
- 8.3.3 Inbiose Sialylated Human Milk Oligosaccharides (HMO) Sales, Value and Gross Margin (2021-2026)
- 8.3.4 Inbiose Sialylated Human Milk Oligosaccharides (HMO) Product Portfolio
- 8.3.5 Inbiose Recent Developments
- 8.4 Kyowa Hakko Bio
- 8.4.1 Kyowa Hakko Bio Company Information
- 8.4.2 Kyowa Hakko Bio Business Overview
- 8.4.3 Kyowa Hakko Bio Sialylated Human Milk Oligosaccharides (HMO) Sales, Value and Gross Margin (2021-2026)
- 8.4.4 Kyowa Hakko Bio Sialylated Human Milk Oligosaccharides (HMO) Product Portfolio
- 8.4.5 Kyowa Hakko Bio Recent Developments
- 8.5 GeneChem Inc.
- 8.5.1 GeneChem Inc. Company Information
- 8.5.2 GeneChem Inc. Business Overview
- 8.5.3 GeneChem Inc. Sialylated Human Milk Oligosaccharides (HMO) Sales, Value and Gross Margin (2021-2026)
- 8.5.4 GeneChem Inc. Sialylated Human Milk Oligosaccharides (HMO) Product Portfolio
- 8.5.5 GeneChem Inc. Recent Developments
- 8.6 FrieslandCampina Ingredients
- 8.6.1 FrieslandCampina Ingredients Company Information
- 8.6.2 FrieslandCampina Ingredients Business Overview
- 8.6.3 FrieslandCampina Ingredients Sialylated Human Milk Oligosaccharides (HMO) Sales, Value and Gross Margin (2021-2026)
- 8.6.4 FrieslandCampina Ingredients Sialylated Human Milk Oligosaccharides (HMO) Product Portfolio
- 8.6.5 FrieslandCampina Ingredients Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Sialylated Human Milk Oligosaccharides (HMO) Value Chain Analysis
- 9.1.1 Sialylated Human Milk Oligosaccharides (HMO) Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Sialylated Human Milk Oligosaccharides (HMO) Sales Mode & Process
- 9.2 Sialylated Human Milk Oligosaccharides (HMO) Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Sialylated Human Milk Oligosaccharides (HMO) Distributors
- 9.2.3 Sialylated Human Milk Oligosaccharides (HMO) Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst